samedan logo
 
 
spacer
home > pmps > winter 2021 > product authentication: a tiered approach to protect brand owners and consumers
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Product Authentication: A Tiered Approach to Protect Brand Owners and Consumers

In recent years, the UN and WHO have reported considerable product recalls – as well as fatalities caused by serious illnesses, including malaria and cancer – due to the consumption of falsified or expired vaccines and drugs. A more concerted, global-centric approach to combat illicit trades, smuggling, counterfeiting, and product diversion is clearly necessary. We have the technology to verify medicine – now we need the will to employ it.

The problem is widespread and confounding. A high percentage of illicit drug fraud is spearheaded by sophisticated counterfeiting organisations that poison consumers, ruin brands, and jeopardise overall faith in the pharmaceutical industry at large. They take the tried and tested quality control methods of pharma manufacturers – standard operating procedures, best manufacturing processes, modern inspection techniques, and supply chain security – and mimic them, often incredibly convincingly. Counterfeits can appear cosmetically identical to authentic products, especially since the advent and proliferation of 3D printing. These drugs might even contain matching base ingredients, but with omitted or vastly reduced active pharmaceutical ingredients (APIs), diminishing or entirely negating a drug’s intended medicinal effects.

Increasingly, cyber-counterfeiting is also common. Such tech-centric fraud infiltrates mobile apps, landing pages, and software (especially for product authentication and verification), and convincingly mimics them to dupe caregivers, consumers, and key trading partners. This way, when barcodes are scanned on the final products, caregivers, supply chain partners, and end users may be directed to a counterfeited authentication page, giving the impression they are engaged with the brand owner’s website or official government oversight organisation.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Jeremy Stillman has been in the security solutions and managed services industry for over 20 years. Following a degree in Business and Marketing, he started his career in information security, evolving into digital supply chain and brand protection. Progressing through consulting, professional services and business development roles, finally leading businesses in the execution of track and trace and brand protection to both global brands and international governments. Jeremy has been a major contributor to the formation of business strategies for industry-leading organisations. Focusing on how digital innovation can increase revenues and maximise efficiencies through the implementation of security systems; enabling organisations to be more agile, competitive, and secure within their market. As the Brand Protection Director for Antares Vision, Jeremy is accountable for all activities relating to anti-diversion and anti-counterfeit solutions for brands and governments.

Dr Roula Karam joined Antares Vision three years ago, and she is currently holding the position of Marketing Research and Innovation Analyst. Roula has had 20 years of experience building a professional and academic/research profile. She holds PhD in Informatics and Mathematics from the University INSA de Lyon, France, after completing a Masters in Telecommunication Engineering. Roula has worked at five different companies and six universities in three different countries as a telecommunication engineer, an ITC associate professor, and scientific researcher. She has been speaker in many international conferences and workshops, publishing many scientific articles and whitepapers on innovative trends applied to Industrial IoT, smart cities, geographic information system (GIS) and crowdsourcing, digital transformation of supply chains, and healthcare innovation.
spacer
Jeremy Stillman
spacer
spacer
spacer
Dr Roula Karam
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avantor® Enters into Distribution Agreement to Supply Agilent Technologies’ Chemistries and Supplies Division products in the U.S. and Canada

Enabling analytical chemistry workflow laboratories full access to Agilent Technologies’ Chemistries & Supplies Division (CSD) portfolio - focusing on chromatography columns, sample preparation products, chemical standards, and spectroscopy supplies through Avantor’s leading digital and direct channels.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement